UTMB Clinical and Translational Science Award
UTMB 临床和转化科学奖
基本信息
- 批准号:9128790
- 负责人:
- 金额:$ 373.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-18 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AcademyAddressAdoptedAdvocacyAfrican AmericanAgingAppointmentAwardBudgetsBurn injuryChildhoodClinical ResearchClinical SciencesClinical TrialsCommunitiesCommunity HealthcareCourse ContentDevelopmentDevicesDiverse WorkforceEducationEducational CurriculumEntrepreneurshipEnvironmentEthicsEvaluationFacultyFosteringFundingGeriatricsGoalsGrowthHealthHealth PersonnelHealth systemHispanicsHistorically Black Colleges and UniversitiesHome environmentHospitalsHumanHybridsImpact evaluationIndividualIndustryInstitutesInstitutionInvestmentsLaboratoriesLeadershipMedicalMissionModelingMolecularMonitorMulti-Institutional Clinical TrialOutcomes ResearchPatient-Focused OutcomesPatientsPediatricsPhasePopulationPositioning AttributePregnancyPublishingPuerto RicoResearchResearch ActivityResearch InfrastructureResearch InstituteResearch PersonnelResearch SupportResource SharingRoleScienceScientistSiteSpecial Populations ResearchStagingSystemTestingTexasTherapeuticTrainingTraining SupportTranslational ResearchTranslationsUnited States National Institutes of HealthUniversitiesWagesWorkbasebench to bedsidecareercohortcommercializationcomparative effectivenessdata sharingevidence baseexperienceimprovedinnovationinter-institutionalleadership developmentlearning communitymedical schoolsmultidisciplinarynamed groupnovelnovel strategiespatient advocacy groupprogramsquality assurancescience educationskillstoolworking group
项目摘要
The CTSA at the University of Texas Medical Branch (UTMB) is located within the Institute for Translational
Science (ITS), one of three free-standing UTMB institutes, established in 2007. In its role as the home for
clinical and translational research, the ITS provides primary tenure-earning faculty appointments to 7 early-
career translational scientists. Over the past 5½ years, we have transformed UTMB's research culture, growing
from an institution that solely valued individual laboratory-oriented research to one that embraces
multidisciplinary translational team (MTT) approaches to addressing significant health problems. We have
developed novel educational curricula, significant clinical research programs in special populations with multi-
site clinical trials (CTs), and provided leadership in the Texas Regional CTSA consortium (TRCC) and
nationally. The mission of the UTMB CTSA hub is to support the health goals of the nation by
generating, testing and disseminating integrative team science, education and best practices through
stakeholder involvement at all stages. Managed by a continuous improvement model using an Innovation
Scorecard, the UTMB CTSA will address four specific aims, to: 1) Train a diverse workforce in the authentic
skills needed to advance all phases of translational research. We have used the team environment as an
educational framework to support the training of diverse learning communities. Our innovation,
entrepreneurship, and team leadership curricula will be used to instill focused, career stage-appropriate
competencies in our trainees. We have led in sharing and disseminating innovative educational content in
entrepreneurship and team science throughout the consortium. 2). Engage stakeholders across all phases
of translational research and CTs. We will extend our substantial bidirectional interactions with stakeholders
from the community, patient advocacy groups, healthcare providers and our Health System to assess health
needs, set CTSA priorities and disseminate competencies. 3). Integrate quality systems through all types
of translational research, including CTs in special populations. We have provided leadership to a
university-wide plan for sustainable support for high-quality CTs through the Office of Clinical Research,
supported by an experienced director, an interoperable Clinical Trial Management System and staff to provide
streamlined support for all phases of CT start-up, quality assurance monitoring, study management and GCP
training. 4). Advance the conduct of translational research through MTT-based innovation. The UTMB
CTSA hub is unique in the national consortium in its systematic application of a hybrid industry-academic MTT
model, and have developed an evidence base on the formation, evaluation, impact and trajectories of
successful MTTs. We will stimulate MTT innovation by promoting team development, leadership development
by a unique Leadership Development Academy, and advancement of therapeutics and devices into Phase I/II
CTs in our “Innovations in Molecular Therapeutics and Devices” Optional Module.
德克萨斯大学医学分部(UTMB)的CTSA位于转化研究所
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Allan R. Brasier其他文献
The NF-κB regulatory network
- DOI:
10.1385/ct:6:2:111 - 发表时间:
2006-06-01 - 期刊:
- 影响因子:3.700
- 作者:
Allan R. Brasier - 通讯作者:
Allan R. Brasier
11: BRD4-MK2 SIGNALING: TARGET FOR CROHN'S DISEASE-ASSOCIATED FIBROSIS.
- DOI:
10.1016/s0016-5085(22)60011-8 - 发表时间:
2022-05-01 - 期刊:
- 影响因子:
- 作者:
Marina Chulkina;Steven B. McAninch;Yi Li;Walter Koltun;Gregory S. Yochum;Bing Tian;Jia Zhou;Ellen J. Beswick;Allan R. Brasier;Iryna V. Pinchuk - 通讯作者:
Iryna V. Pinchuk
33 NOVEL SMALL MOLECULE BRD4 INHIBITORS SUPPRESS COLONIC INFLAMMATION IN MOUSE MODELS OF INFLAMMATORY BOWEL DISEASE
- DOI:
10.1016/s0016-5085(21)00770-8 - 发表时间:
2021-05-01 - 期刊:
- 影响因子:
- 作者:
Zhiqing Liu;Gabriela Uribe;Yi Li;Pingyuan Wang;Haiying Chen;Yingzi Cong;Allan R. Brasier;Iryna V. Pinchuk;Jia Zhou;Bing Tian - 通讯作者:
Bing Tian
Transcriptional regulation of angiotensinogen gene expression.
血管紧张素原基因表达的转录调控。
- DOI:
- 发表时间:
1999 - 期刊:
- 影响因子:0
- 作者:
Allan R. Brasier;Youqi Han;C. T. Sherman - 通讯作者:
C. T. Sherman
Pollen-induced oxidative DNA damage response regulates miRNAs controlling allergic inflammation
- DOI:
- 发表时间:
2017 - 期刊:
- 影响因子:
- 作者:
Leopoldo Aguilera-Aguirre;Wenging Hao;Lang Pan;Xiaoxue Li;Alfredo Saavedra-Molina;Attila Bacsi;Zsolt Radak;Sanjiv Sur;Allan R. Brasier;Xueqing Ba;Istvan Boldogh - 通讯作者:
Istvan Boldogh
Allan R. Brasier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Allan R. Brasier', 18)}}的其他基金
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10373575 - 财政年份:2021
- 资助金额:
$ 373.89万 - 项目类别:
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNA
增强子样启动子及其编码lncRNA对粘膜IRF1/IFN-III抗病毒反应的表观遗传控制
- 批准号:
10495267 - 财政年份:2021
- 资助金额:
$ 373.89万 - 项目类别:
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma
过敏性哮喘粘膜抗病毒免疫的表观遗传机制重编程
- 批准号:
10553704 - 财政年份:2019
- 资助金额:
$ 373.89万 - 项目类别:
Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic Asthma
过敏性哮喘粘膜抗病毒免疫的表观遗传机制重编程
- 批准号:
10371977 - 财政年份:2019
- 资助金额:
$ 373.89万 - 项目类别:
Transcriptional Elongation in NF-kB Mediated Inflammation
NF-kB 介导的炎症中的转录延伸
- 批准号:
8710493 - 财政年份:2013
- 资助金额:
$ 373.89万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 373.89万 - 项目类别:
Research Grant














{{item.name}}会员




